CY1125531T1 - Μεθοδος παρασκευης της 5-[[4-[2-[5-(1- υδροξυαιθυλ)-2-πυριδι-νυλ]αιθοξυ]φαινυλ]μεθυλ]- 2,4-θειαζολιδινεδιονη και των αλατων της - Google Patents
Μεθοδος παρασκευης της 5-[[4-[2-[5-(1- υδροξυαιθυλ)-2-πυριδι-νυλ]αιθοξυ]φαινυλ]μεθυλ]- 2,4-θειαζολιδινεδιονη και των αλατων τηςInfo
- Publication number
- CY1125531T1 CY1125531T1 CY20221100593T CY221100593T CY1125531T1 CY 1125531 T1 CY1125531 T1 CY 1125531T1 CY 20221100593 T CY20221100593 T CY 20221100593T CY 221100593 T CY221100593 T CY 221100593T CY 1125531 T1 CY1125531 T1 CY 1125531T1
- Authority
- CY
- Cyprus
- Prior art keywords
- salts
- thiazolidinedione
- pyridinyl
- ethoxy
- hydroxyethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/127—Preparation from compounds containing pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382648 | 2016-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125531T1 true CY1125531T1 (el) | 2026-02-25 |
Family
ID=57799523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100593T CY1125531T1 (el) | 2016-12-23 | 2022-09-06 | Μεθοδος παρασκευης της 5-[[4-[2-[5-(1- υδροξυαιθυλ)-2-πυριδι-νυλ]αιθοξυ]φαινυλ]μεθυλ]- 2,4-θειαζολιδινεδιονη και των αλατων της |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11124505B2 (https=) |
| EP (1) | EP3559010B1 (https=) |
| JP (2) | JP7294661B2 (https=) |
| KR (1) | KR102609373B1 (https=) |
| CN (1) | CN110198945B (https=) |
| BR (1) | BR112019012972B1 (https=) |
| CA (1) | CA3046744A1 (https=) |
| CY (1) | CY1125531T1 (https=) |
| DK (1) | DK3559010T3 (https=) |
| ES (1) | ES2926580T3 (https=) |
| HR (1) | HRP20221067T1 (https=) |
| HU (1) | HUE059604T2 (https=) |
| IL (1) | IL267557B (https=) |
| LT (1) | LT3559010T (https=) |
| MX (1) | MX379709B (https=) |
| PL (1) | PL3559010T3 (https=) |
| PT (1) | PT3559010T (https=) |
| SI (1) | SI3559010T1 (https=) |
| WO (1) | WO2018116281A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2926580T3 (es) | 2016-12-23 | 2022-10-27 | Minoryx Therapeutics S L | Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma |
| CN112823004A (zh) | 2018-06-06 | 2021-05-18 | 米尼奥尔克斯治疗有限公司 | 5-[[4-[2-[5-乙酰基吡啶-2-基]乙氧基]苄基]-1,3-噻唑烷-2,4-二酮及其盐的用途 |
| EP3801515B1 (en) | 2018-06-06 | 2025-04-09 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
| CN112512524A (zh) | 2018-06-06 | 2021-03-16 | 米尼奥尔克斯治疗有限公司 | 给予治疗有效量的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮的方法 |
| EP4642456A1 (en) | 2022-12-28 | 2025-11-05 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
| WO2024231881A2 (en) | 2023-05-09 | 2024-11-14 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69231886T2 (de) * | 1991-04-11 | 2002-03-28 | Pharmacia & Upjohn Co., Kalamazoo | Thiazolidindionderivate, herstellung und anwendung |
| US5952509A (en) | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
| US6067749A (en) | 1996-07-11 | 2000-05-30 | Tasmanian Alkaloids Pty. Ltd. | Papaver somniferum strain with high concentration of thebaine and oripavine |
| US5869669A (en) | 1996-07-26 | 1999-02-09 | Penick Corporation | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
| HUP0304096A2 (hu) | 2003-12-19 | 2005-08-29 | Richter Gedeon Vegyészeti Gyár Rt. | Eljárás pioglitazon hidrogénklorid előállítására és intermedierjei |
| GB0421687D0 (en) | 2004-09-30 | 2004-11-03 | Johnson Matthey Plc | Preparation of opiate analgesics |
| CA2594666A1 (en) | 2005-02-16 | 2006-08-24 | Micromet Ag | Use of activated polymers for separation of protein and polypeptide multimers |
| US20090247560A1 (en) * | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| JPWO2008136428A1 (ja) * | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| EP2855489B1 (en) * | 2012-04-26 | 2017-01-04 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| WO2014152843A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| EA202091120A3 (ru) | 2014-04-02 | 2020-12-30 | Минорикс Терапьютикс С.Л. | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы |
| ES2926580T3 (es) | 2016-12-23 | 2022-10-27 | Minoryx Therapeutics S L | Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma |
-
2017
- 2017-12-22 ES ES17829042T patent/ES2926580T3/es active Active
- 2017-12-22 SI SI201731203T patent/SI3559010T1/sl unknown
- 2017-12-22 HR HRP20221067TT patent/HRP20221067T1/hr unknown
- 2017-12-22 BR BR112019012972-3A patent/BR112019012972B1/pt active IP Right Grant
- 2017-12-22 EP EP17829042.5A patent/EP3559010B1/en active Active
- 2017-12-22 HU HUE17829042A patent/HUE059604T2/hu unknown
- 2017-12-22 US US16/470,866 patent/US11124505B2/en active Active
- 2017-12-22 KR KR1020197021529A patent/KR102609373B1/ko active Active
- 2017-12-22 WO PCT/IB2017/058374 patent/WO2018116281A1/en not_active Ceased
- 2017-12-22 PL PL17829042.5T patent/PL3559010T3/pl unknown
- 2017-12-22 JP JP2019534154A patent/JP7294661B2/ja active Active
- 2017-12-22 DK DK17829042.5T patent/DK3559010T3/da active
- 2017-12-22 LT LTEPPCT/IB2017/058374T patent/LT3559010T/lt unknown
- 2017-12-22 MX MX2019007327A patent/MX379709B/es unknown
- 2017-12-22 PT PT178290425T patent/PT3559010T/pt unknown
- 2017-12-22 CN CN201780084302.3A patent/CN110198945B/zh active Active
- 2017-12-22 CA CA3046744A patent/CA3046744A1/en active Pending
-
2019
- 2019-06-20 IL IL267557A patent/IL267557B/en unknown
-
2021
- 2021-09-20 US US17/479,838 patent/US11731963B2/en active Active
-
2022
- 2022-09-06 CY CY20221100593T patent/CY1125531T1/el unknown
-
2023
- 2023-02-06 JP JP2023016009A patent/JP2023052918A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20190389852A1 (en) | 2019-12-26 |
| CN110198945A (zh) | 2019-09-03 |
| HRP20221067T1 (hr) | 2022-11-25 |
| IL267557B (en) | 2021-10-31 |
| EP3559010A1 (en) | 2019-10-30 |
| IL267557A (en) | 2019-08-29 |
| PL3559010T3 (pl) | 2022-11-21 |
| BR112019012972B1 (pt) | 2023-04-18 |
| SI3559010T1 (sl) | 2022-10-28 |
| PT3559010T (pt) | 2022-09-01 |
| MX379709B (es) | 2025-03-11 |
| HUE059604T2 (hu) | 2022-11-28 |
| ES2926580T3 (es) | 2022-10-27 |
| KR20190100300A (ko) | 2019-08-28 |
| BR112019012972A2 (pt) | 2019-12-31 |
| US20220204496A1 (en) | 2022-06-30 |
| DK3559010T3 (da) | 2022-08-15 |
| US11731963B2 (en) | 2023-08-22 |
| JP2023052918A (ja) | 2023-04-12 |
| JP2020502228A (ja) | 2020-01-23 |
| CN110198945B (zh) | 2023-06-27 |
| LT3559010T (lt) | 2022-10-10 |
| EP3559010B1 (en) | 2022-06-08 |
| CA3046744A1 (en) | 2018-06-28 |
| JP7294661B2 (ja) | 2023-06-20 |
| KR102609373B1 (ko) | 2023-12-01 |
| MX2019007327A (es) | 2019-09-02 |
| WO2018116281A1 (en) | 2018-06-28 |
| US11124505B2 (en) | 2021-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125531T1 (el) | Μεθοδος παρασκευης της 5-[[4-[2-[5-(1- υδροξυαιθυλ)-2-πυριδι-νυλ]αιθοξυ]φαινυλ]μεθυλ]- 2,4-θειαζολιδινεδιονη και των αλατων της | |
| AR116394A2 (es) | Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
| CY2018031I2 (el) | Αλατα και πολυμορφα της 8-φθορο-2-{4-[(μεθυλαμινο)μεθυλο]φαινυλο}-1,3,4,5-τετραϋδρο-6η-αζεπινο[5,4,3-cd]ινδολο-6-ονης | |
| IL223002A0 (en) | Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide | |
| CL2008002142A1 (es) | Compuestos derivados de 2-amino-6-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}tio)-4-[4-(2-hidroxietoxi) fenil] piridin-3,5-dicarbonitrilo; procedimiento de preparacion; composicion farmaceutica y uso en enfermedades cardiovasculares. | |
| SMT201500223B (it) | Polimorfi e sali di n-[5-[4-(5-{[(2R,6S)-2,6-dimetil-4-morfolinil]metil}-1,3-ossazol-2-il)-1H-indazol-6-IL]-2-(metilossi)-3-piridinilÜmetansolfonammide | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| JP2016506958A5 (https=) | ||
| NZ592297A (en) | 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents | |
| SI2978752T1 (en) | 6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD | |
| EA202091120A3 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| NZ629636A (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions | |
| HUE054346T2 (hu) | 5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-dion nem-alkoholos zsírmáj-betegség kezelésére | |
| IL279183A (en) | Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione | |
| IL279186A (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts | |
| SI3801515T1 (sl) | 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion in soli za uporabo pri zdravljenju mitohondrijske bolezni | |
| NZ602883A (en) | Novel synthesis for thiazolidinedione compounds | |
| NZ716494A (en) | Processes and intermediates for the preparation of a pde10 inhibitor | |
| HK40050840A (en) | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione | |
| MY180730A (en) | Azole benzene derivative and crystalline form thereof | |
| EP3170819A4 (en) | Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same | |
| HK40049678A (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts | |
| RU2017115036A (ru) | Производные бензилгидроксида, их получение и их терапевтическое применение | |
| RU2016131300A (ru) | Новые производные имидазолидин-2, 4-диона |